Loading clinical trials...
Loading clinical trials...
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Conditions
Interventions
RMC-4630
Cobimetinib
+1 more
Locations
24
United States
Honor Health Research Institute
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
UC Irvine - Chao Family Comprehensive Cancer Center
Orange, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
UC San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Start Date
July 2, 2019
Primary Completion Date
February 8, 2022
Completion Date
February 8, 2022
Last Updated
June 26, 2023
NCT06144671
NCT04570423
NCT06132828
NCT07177937
NCT06926283
NCT07489378
Lead Sponsor
Revolution Medicines, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions